On Jul. 29, 2020, Quest Diagnostics announced that the FDA had granted emergency use authorization for a new laboratory technique that speeds the process of extracting viral RNA from specimens* and will enable the company to expand its daily capacity of COVID-19 molecular diagnostic tests on behalf of patients in the U.S.